WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Trilogy Home Healthcare
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Industry Outlook
Virica Biotech | January 17, 2024
Virica Biotech Inc. (“Virica”), a leading developer of cell enhancers for scaling of viral vector as well as cell and gene therapy manufacturing will expand its bioprocessing services through a partnership with Carleton University. Slated to open this spring, Virica’s new facility at the university multiplies the Company’s capacity to provide high throughput virology services for customers looking to optimize production of their cell and gene therapies. &...
MedTech
Businesswire | June 08, 2023
Novir, an emerging biotechnology company, focused on pioneering the pre-care pathway to better health, has announced today the launch of their refreshed brand, dedicated to showcasing the evolution Novir has taken from a COVID-19 testing and vaccination provider to a more comprehensive healthcare solution committed to advancing healthcare from sick-care to pre-care by offering affordable, accessible, and reliable screening solutions to anyone, anywhere, anytime. Since their ince...
Diverse Biotech | May 04, 2020
Diverse Biotech, Inc. www.diversebiotech.com has announced the U.S. Food & Drug Administration (FDA) has granted an orphan-drug designation request for one of its investigational new therapies for treatment of newly diagnosed glioblastoma, in conjunction with standard treatment, following adjuvant combined chemo-radiation. Orphan designation qualifies the sponsor of the drug for various development incentives of the ODA, (Orphan Drug Act) including tax credits for qualified clinical te...
Cell and Gene Therapy
Elastrin Therapeutics Inc. | January 17, 2022
Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the formation of its Scientific Advisory Board. The Board is comprised of leading industry and university experts in cardiovascular research and clinical development. Former CMO of Elastrin Therapeutics, Dr. Pedro M. Quintana Diez, will act as chairman. Elastrin Therapeutics’ lead asset ELT-001 is an EDTA...
Medical
Video
Whitepaper
Industrial Impact
Industrial Impact, Medical
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE